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mal for the conditions used and support the use of immunoads-A novel immunoadsorption device for removing b2-microglob-
orption for the removal of b2m.ulin from whole blood.
Background. High plasma levels of b2-microglobulin (b2m)
have been implicated in the formation of the severely destruc-
tive and potentially fatal amyloid deposits that are characteris-
End-stage renal disease (ESRD) may be complicatedtic of dialysis-related amyloidosis (DRA). Conventional renal
by an incapacitating progressive disorder known as dial-replacement technologies remove insufficient quantities of b2m
to normalize plasma levels. This limitation arises because of ysis-related amyloidosis (DRA) [1]. Although the patho-
nonspecific adsorptive qualities and reliance on size exclusion, physiology of DRA is not fully understood, retention
which can also remove other middle molecular weight proteins. of b2-microglobulin (b2m; 11.8 kD), the amyloid fibrilThese nonspecific approaches also make it difficult to evaluate
precursor, is an apparent prerequisite for the conditionthe role and contribution of middle molecular weight molecules
to the pathology of DRA and other morbidities of end-stage [2]. b2m is secreted by all nucleated cells and accumulates
renal disease. A high-affinity and biologically specific approach in the extracellular fluid as the glomerular filtration rate
could target a protein, prevent a significant loss of other impor- declines. High plasma b2m concentrations, along withtant molecules, and improve the apparent adsorption rate within
b2m-derived advanced glycation end products (AGEs),an extracorporeal device.
have been implicated in the formation of the severelyMethods. Agarose-immobilized murine anti-human b2m
monoclonal antibodies were used in a Vortex Flow Plasmaphe- destructive and potentially fatal amyloid deposits that
retic Reactor (VFPR) to remove donor baseline and controlled are characteristic of DRA [3–6]. Except for kidney trans-
amounts of recombinant b2m from human blood in vitro. The plantation, there are currently no widely available thera-extracorporeal circuit was hemoperfused at 200 mL/min for
pies to prevent or treat this condition effectively. Never-two hours.
Results. The immunoadsorptive media had a binding site theless, studies have shown that there is a correlation
density of 30 mg b2m per mL of settled gel. The VFPR cleared between the removal of b2m from blood and a delay in
baseline quantities of donor b2m below detectable limits of the the onset of the disease [7–9].assay. The experiments with higher initial b2m concentrations
Currently, all clinically approved renal replacementreached an equilibrium concentration within 20 minutes, corre-
therapies that remove b2m are nonspecific. These thera-sponding to a 92% clearance. No deleterious hemocompatibil-
ity issues were observed (complete blood count, total protein, pies, which are based on membrane transport and hy-
and plasma free hemoglobin). drophobic adsorption, remove insufficient quantities of
Conclusions. The adsorptive kinetics of the VFPR are opti-
b2m while randomly depleting other proteins of similar
size [10, 11]. A method that specifically removes b2m from
blood would prevent a significant loss of proteins that1 Dr. Ameer and Mr. Grovender contributed equally to this study.
are needed by the patient. In this regard, high-affinity
Key words: dialysis-related amyloidosis, extracorporeal immunoad-
immunoadsorption therapies are able to target specificsorption, vortex flow, renal replacement therapy, middle molecular
weight molecules, hemocompatibility. proteins, an advantage that could be used for diagnostic
purposes. The removal of b2m from human plasma hasReceived for publication August 15, 2000
been investigated using antibodies immobilized ontoand in revised form October 23, 2000
Accepted for publication October 25, 2000 small porous particles (45 to 165 mm) [12–14]. However,
these studies were small-scale affinity chromatographyÓ 2001 by the International Society of Nephrology
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experiments that did not address the challenge of com- ate, pH 8.3). The fluid in the gel void volume was re-
moved, and the activated agarose was combined withbining b2m immunoadsorption with plasmapheresis in a
clinically feasible system. Therefore, research into device the protein to be immobilized (167 mg of BBM.1 via
Bradford dye assay and 174 mg BSA by dry weight) indesign and scale-up is needed to facilitate the use of
immunoadsorption in renal replacement therapies. 82 mL of phosphate-buffered saline (PBS), pH 7.4. The
protein was allowed to bind to the activated agaroseWe hypothesized that an immunoaffinity-based extra-
corporeal vortex flow plasmapheretic reactor (VFPR) suspension for 40 hours at 48C with gentle mixing. The
buffer was removed from the agarose gel and assayedcould be developed to specifically remove b2m from hu-
man blood. Our long-term goal was to use recombinant, for its residual protein concentration (Bradford assay
for BBM.1 and change in absorbance at 280 nm forsingle-chain Fv antibody fragment (scFv) technology to
develop a potentially less expensive immunoadsorptive BSA). The activated gel was quenched by mixing it with
a lysine buffer (0.2 mol/L lysine, 0.5 mol/L sodium chlo-media (fermentation vs. tissue culture). Demonstrating
the feasibility of this technology platform, using DRA ride, 0.1 mol/L sodium bicarbonate, pH 8.3) for one hour
at 48C. The gel was rinsed quickly with 500 mL PBS andas a model disease, supports the tailored application of
this approach for the removal of other target molecules rinsed overnight with 200 mL PBS at 48C. The following
day, the overnight rinse was replaced with fresh PBS. Awith pathologic consequences.
sample was incubated for one hour at 378C to check the
thermal stability of the immobilized protein (Bradford
METHODS
assay). Coomassie-stained sodium dodecyl sulfate-poly-
Assays acrylamide gel electrophoresis (SDS-PAGE) was used
to check for protein in the lysine-quenching buffer andSerum and plasma b2m concentrations were assayed
with the b2-micro radioimmunoassay (RIA) kit available PBS rinses.
from Pharmacia-Upjohn (Kalamazoo, MI, USA), while
Vortex Flow Plasmapheretic Reactorthe buffer b2m concentrations were determined by using
an extinction coefficient of 20,065 mol/L21 cm21 at 280 nm. A VFPR is a Taylor-Couette vortex flow device with
a modified outer cylinder (Fig. 1). Taylor-Couette vortexThis value was derived from the published amino acid
sequence of human b2m [15], and the equation reported flow is a phenomenon that arises under certain condi-
tions in liquid flowing axially between two counter-rotat-by Pace et al [16]. Bradford protein assays were per-
formed according to the dye manufacturer’s instructions ing concentric cylinders [20]. The modification of the
Taylor-Couette vortex flow device to yield a VFPR in-(Bio-Rad, Hercules, CA, USA), using a bovine g globu-
lin standard (Pierce, Rockford, IL, USA). Plasma-free cluded counterboring an adsorptive chamber into the
outer cylinder and sealing it with a track-etched, 1 micronhemoglobin assays were performed according to the in-
structions of a kit purchased from Sigma Chemical (St. pore-size polyester membrane (Whatman, Kent, UK).
The Taylor vortices in the inner compartment inducedLouis, MO, USA). Complete blood counts and total
protein assays were performed at the Massachusetts In- the periodic undulation of the microporous membrane,
which in turn fluidized the gel beads in the adsorptivestitutes of Technology Medical Laboratory (Cambridge,
MA, USA). compartment and reduced the cell polarization layer. A
dedicated peristaltic pump (“plasma pump”) controlled
Protein immobilization the plasma flow rate through the microporous membrane
and the adsorptive compartment. These mechanisms en-BBM.1 monoclonal antibody (HB-28 hybridoma pur-
chased from ATCC, Manassas, VA, USA) [17, 18] and abled the VFPR to perform high-flux plasmapheresis
in series with fluidized bed adsorption. More detailedbovine serum albumin (BSA) were each immobilized onto
48 mL settled volumes of Sepharose CL-4B agarose gel descriptions of the VFPR have been published elsewhere
[21–23].beads (Amersham-Pharmacia, Uppsala, Sweden) using
a modified version of a previously described method [19].
Recombinant b2m preparationThe gel beads were rinsed with 1 L of ultrapurified
water and then combined with 50 mL of ultrapurified The b2m Escherichia coli expression vector [24] was
a generous gift from the Wiley Laboratory (Cambridge,water and 100 mL of 2 mol/L sodium carbonate. After
being chilled on ice, the agarose gel suspension was acti- MA, USA), and the recombinant protein was produced
in a fashion similar to those previously described [25, 26].vated for five minutes with 20% wt/vol cyanogen bro-
mide (each gram was predissolved in 1.5 mL acetoni- Each liter of Luria-Bertani medium (fortified with 0.4%
wt/vol glucose and 0.100 mg/mL ampicillin) was inocu-trile). The activated gel was rinsed sequentially with 1 L
of each of the following ice-chilled fluids: ultrapurified lated with frozen stock, incubated at 378C, and induced
with 0.5 mmol/L isopropyl b-D-thiogaloctopyranosidewater, 1 mmol/L hydrochloric acid, and bicarbonate
buffer (0.5 mol/L sodium chloride, 0.1 sodium bicarbon- during the log growth phase. The bacteria was centri-
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Fig. 1. Diagram outlining the design of the vor-
tex flow plasmapheretic reactor (VFPR; 6.5 3
15 cm). The total reactor volume was 125 mL,
which was distributed among the whole blood,
adsorptive plasma, and plasma collection cham-
bers as 50, 70, and 5 mL, respectively. The
volume of the plasma tubing was 10 mL. The
whole blood path is shown in dark gray, while
regions accessible to only plasma are shown
in light gray. The settled volume of agarose
gel beads was 48 mL.
fuged at 5 k 3 g for 20 minutes and resuspended in 50 quantitate the capacity of the immunoadsorptive media.
mmol/L Tris-HCl, 25% wt/vol sucrose, 1 mmol/L sodium Briefly, 10 mL of 50% gel/PBS suspension, 30 mL of
ethylenediaminetetraacetic acid (EDTA), 10 mmol/L 5 micron-filtered porcine serum (GIBCO BRL, Gaithers-
dithiothreitol (DTT), pH 8.0. Cell lysis and DNA degra- burg, MD, USA), and either 0.23, 0.31, or 0.40 mg of
dation were effected through the addition of 1 mg/mL rb2m (stock: 0.94 6 0.02 mg/mL in elution buffer) were
lysozyme, 0.1 mg/mL DNase I (Sigma DN-25), 5 mmol/L combined in 50 mL polypropylene tubes (Corning, Corn-
magnesium chloride, 1% Triton X-100, 1% sodium deoxy- ing, NY, USA). The tubes were equilibrated under well-
cholate, 10 mmol/L DTT, and 70 mmol/L sodium chlo- mixed conditions for at least one hour at 378C. The rb2m-
ride. The insoluble protein was rinsed several times with adsorptive capacity of the agarose-immobilized mono-
50 mmol/L Tris-HCl, 100 mmol/L sodium chloride, clonal antibody was calculated using the formula:
1 mmol/L EDTA, 0.5% Triton X-100, and 1 mmol/L
DTT, pH 8.0, and one final time with 50 mmol/L Tris- ds 5
Vtotal
Vgel
(C0 2 CEq) (Eq. 1)
HCl, 1 mmol/L EDTA, pH 8.0. The washed inclusion
body protein was solubilized in 8 mol/L urea, 25 mmol/L where ds is the adsorption site density (mg rb2m per L2-[N-morpholino]ethanesulfonic acid (MES), 10 mmol/L
settled gel); Vtotal is the total volume of the system (mL);EDTA, and 0.1 mmol/L DTT, pH 6.0, and was ultracen-
Vgel is the settled-volume of gel (mL); C0 is the initialtrifuged for 30 minutes at 258C and 186,000 3 g. The
diluted concentration of rb2m in the system (mg/L), anddenatured protein was refolded through dilution into
CEq is the equilibrium concentration of desorbed rb2m100 mmol/L Tris-HCl, 400 mmol/L l-arginine-HCl,
(mg/L).2 mmol/L EDTA, 0.5 mmol/L oxidized glutathione,
5 mmol/L reduced glutathione, pH 8.0. The refolded b2m Clearance of b2m from human blood with anwas purified via size-exclusion chromatography using immunoadsorptive VFPR
prep-grade Superose 12 resin (Amersham-Pharmacia),
All experiments with human blood were approved byeluted with 20 mmol/L Tris-HCl, 150 mmol/L sodium
the Massachusetts Institute of Technology Committeechloride, pH 8.0. In order to remove residual refolding
on the Use of Humans as Experimental Subjects. Healthybuffer, the b2m was dialyzed against the elution buffer
volunteer blood donors read and signed informed con-with a 6 to 8 kD membrane (Spectrum Laboratories,
sent forms. The staff at the Children’s Hospital BloodRancho Dominguez, CA, USA).
Donor Center (Boston, MA, USA) performed the phle-
Capacity of the immoadsorptive media botomies. Each donation (450 mL nominal volume) was
used the same day it was received and had 63 mL ofPorcine serum, loaded with three different saturating
concentrations of recombinant b2m (rb2m), was used to citrate phosphate dextrose adenine solution added as
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Fig. 2. Diagram of the circuit used to study
the clearance of b2-microglobulin (b2m) from
human blood. The overall circulation flow rate
was set at 200 mL/min. The plasma pump was
calibrated to 50 mL/min, and the rotation rate
was set at 1150 r.p.m. The volume of the tubing
running from the blood bag to the VFPR was
60 mL, while the return tubing was 5 mL.
The blood temperature at the VFPR inlet and
outlet was 358C during the clearance of recom-
binant human b2m (rb2m).
Table 1. Capacity of the immunoadsorptive mediaan anticoagulant (Baxter, McGaw Park, IL, USA). The
VFPR and circuit tubing were primed with 0.9% wt/vol Initial concentration Final concentration Binding site density ds
C0 (mg/L, N 54) CEq (mg/L) (mg b2m/L settled gel)sodium chloride (USP grade; Abbott Laboratories, North
5.860.1 2.160.0 3060.0Chicago, IL, USA), and the agarose gel was injected into
7.760.2 3.860.2 3261.0the adsorptive compartment. The blood bag was placed
10.060.0 6.460.3 2962.0
on a shaker and connected to the VFPR in a closed-
loop circuit (Fig. 2). Before the plasma pump and VFPR
cylinder were turned on, the main circuit pump was run
unless otherwise noted. Analysis of variance (ANOVA)for five minutes to mix the blood with the saline outside
was used to determine the significance of the differencesof the plasma chambers and plasma line. During the
among three or more means, while the Student’s two-first 60 minutes of a two-hour hemoperfusion, the native
sample t test was used to compare pairs of means. Thedonor b2m was cleared from the circuit by running the
criterion for significance was a two-tailed P value of 0.05.plasma pump and the inner VFPR cylinder. Samples
were taken before and after this period, and the adsorp-
tive chamber was flushed with 0.9% wt/vol sodium chlo- RESULTS
ride (BBM.1 gel only). Protein immobilization
The immunoadsorptive media (but not the BSA gel)
Most of the BBM.1 (92%) and the BSA (97%) boundwas regenerated with 1.5 L of 0.3 mol/L glycine-HCl,
to the activated agarose gel, yielding immobilization den-
pH 2.8. The regenerated BBM.1 gel was rinsed with 1.5 L sities of 3.0 and 3.5 mg/mL settled gel, respectively. The
of PBS and reinjected into the adsorptive chamber of lysine-quenching buffer and the PBS rinses did not show
the VFPR. Recombinant human b2m (1.5 mg in elution significant amounts of BBM.1 on sodium dodecyl sula-
buffer) was injected into the circuit and allowed to mix fate-polyacrylamide gel electrophoresis (SDS-PAGE) as
with the blood for five minutes, after which samples were compared with equal volume samples of BBM.1 in PBS
taken. The rb2m was cleared from the circuit by turning from before and after activated substrate contact. Pro-
on the plasma pump and VFPR cylinder. Samples were tein leaching, after one hour of 378C incubation, in the
taken over a period of 60 minutes, and the media was BBM.1 and BSA 1 samples was found to be only 2.9 6
regenerated as before (both BBM.1 and BSA). The sam- 0.7 and 0.5 6 0.2 mg/L PBS, respectively.
ples collected were assayed for their total protein,
Capacity of the immunoadsorptive mediaplasma-free hemoglobin, complete blood count, and b2m
concentration. System efficacy was quantitated by calcu- Table 1 shows the results from the adsorption capacity
lating the conversion of b2m adsorption, Xadsorption, as measurements. The rb2m binding capacity of the immu-
noadsorptive media, ds, was calculated to be 30 6 2 mgshown by Equation 2 (dimensionless). Here, Minitial and
rb2m/L settled gel. Assuming bivalent BBM.1–b2m bind-Mfinal are the initial and final masses (mg) of desorbed
ing, this value corresponds to a BBM.1 efficiency of 6%.b2m in the system, respectively.
There was no apparent effect of the 0.3 mol/L glycine




Clearance of b2m from human blood with an
Statistical analysis immunoadsorptive VFPR
Observed variables are reported as the mean 6 SEM. The average total volume, native b2m concentration,
and hematocrit of the anticoagulated human blood wasAll experiments were performed in triplicate (N 5 3),
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Table 2. Clearance of beta-2-microglobulin from human blood by the VFPR in vitro
Native Recombinant
Minitial mg Mfinal mg Xadsorption Minitial mg Mfinal mg Xadsorption
BBM.1 (N54) 0.4860.07 0.0a 100%66% 1.4360.08 0.1060.02 92%62%
BSA (N53) 0.3760.04 0.2660.01 29%66% 1.8060.05 1.8960.11 0.0a
Significance P.0.05 P,0.002 P,0.0005 P,0.02 b b
a Below detectable limits
b Values were not compared due to the significant difference of the initial concentrations
(HbP) was 4.3 6 1.1 mg/dL, while HbP at the end of
native b2m removal (1 h) was 8.9 6 2.2 g/dL. This increase
corresponded to 0.33 mg/dL per circuit pass. A HbP of
0.6 mg/dL per pass through a hemodialyzer is generally
considered acceptable [21].
DISCUSSION
Although the clinical pathology of DRA is not fully
understood, it has been shown that removal of b2m can
apparently delay the onset of the disease and improve
symptoms [7, 9, 10]. For the first time, to our knowledge,
we have shown the feasibility of removing b2m from
whole blood within a single device via immunoadsorp-
tion. As a first step, agarose-immobilized murine anti-Fig. 3. Kinetics of rb2m clearance from human blood with a BBM.1-
loaded VFPR in vitro. Symbols are: (r) blood bag; (---) plasma line. human b2m monoclonal antibodies (BBM.1) were usedError bars represent the standard error of the mean (SEM, N 5 4).
in a VFPR to remove both native and recombinant hu-
man b2m from human blood in vitro. The characteristics
and advantages of the VFPR have been previously
shown for the enzymatic neutralization of heparin to529 6 6, 1.3 6 0.1, and 0.38 6 0.01 mg/L, respectively
potentially make heparin anticoagulation during open-(N 5 7). The final native b2m concentration of the BSA
heart surgery and dialysis safer [21, 27, 28]. Porous aga-circuit was 0.5 6 0.0 mg/L, while that of the BBM.1
rose gel beads were suspended within the adsorptive/circuit was below detectable limits. Table 2 presents the
reactive compartment and did not come into contactobserved native and rb2m adsorption conversions for the
with the blood cells, thereby minimizing hemolysis. TheBBM.1 antibody and BSA control protein matrices. The
agarose gel beads used in this study were hydrophilickinetics of rb2m removal by the VFPR loaded with
and did not have any significant net surface charge, whichBBM.1 gel are illustrated by Figure 3. The relatively low
could result in ion exchange phenomena. Furthermore,plasma line concentration (,0.5 mg/L) indicates that the
the common use of agarose gel beads in size exclusionapparent b2m adsorption rate within the plasma chamber
chromatography also reflects its low protein-bindingwas not limiting. Furthermore, the time scale of b2m
characteristic. Our results demonstrated that a VFPR isclearance from the blood bag was in agreement with
able to clear low concentrations of b2m from whole bloodthat obtained by dividing the total blood path volume
at a clinically relevant flow rate, without any deleterious(445 mL) by the plasma flow rate (50 mL/min). The
effects on the cellular blood components, total protein,initial and final rb2m concentrations in the BBM.1 circuit
or plasma-free hemoglobin. Other factors, such as com-were 3.2 6 0.2 and 0.2 6 0.1 mg/L, respectively. This
plement activation, could potentially be an issue withobserved initial value was in agreement with the value
agarose gel beads. However, the immobilization chemis-(3.4 mg/L) predicted by dividing the mass of injected
try and support used in the study were model systems torb2m (1.5 mg) by the cell-free volume of the blood bag,
establish feasibility. The ability of the VFPR to performcircuit tubing, and VFPR blood chamber (445 mL). The
adsorption, without a separate plasma filter, should po-mass of rb2m adsorbed by the BBM.1 was 28 6 2 mg/L
tentially render the device convenient for use duringgel (settled volume), which was not significantly different
dialysis. Furthermore, the relatively low whole bloodfrom the value of ds measured a priori.
priming volume of 50 mL should minimize hemodilution.Tables 3 and 4 report the effects of the VFPR circuit
Our approach offers several potential advantages. Theon cellular blood elements and total protein, respec-
tively. The donor bag plasma-free hemoglobin level VFPR design overcomes the hemolysis and mass-trans-
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Table 3. Complete blood count data for the BBM.1 VFPR experiments (N54)
Native Recombinant
Diluted bagb Initial Final Initial Final
Erythrocytea 10 6/lL 3.3960.08 3.2360.20 3.2660.08 3.1860.11 3.5160.15
Leukocytea 10 3/lL 4.260.5 4.260.5 3.960.5 4.060.5 4.360.5
Plateleta 10 3/lL 164613 175615 162613 161618 172620
a No significant differences were found among the mean observed values for each count type over the two hour period (ANOVA, P . 0.4)
b Concentrations determined by multiplying the donor blood bag measurement by the dilution factor resulting from the saline priming volume
Table 4. Total protein data for the VFPR BBM.1 experiments and BSA controls
Native Recombinant
Bag Initial Final Initial Final
BBM.1a g, N54 19.360.4 18.160.5 19.761.4 14.860.4 15.860.3
BSAb g, N53 19.160.5 17.760.4 18.560.4 c 19.760.6
Significanced P.0.8 P.0.5 P.0.5 N.A. P,0.005
a No significant differences were found among the mean observed values during the native phase (ANOVA, P . 0.4). A significant decrease was found between
the native and recombinant phases (ANOVA, P , 0.001), which was due to the flushing of the adsorpitve compartment and the regeneration of the media.
b No significant differences were found among the mean observed values (ANOVA, P . 0.1)
c This sample was equivalent to the “Final Native” sample because the BSA gel was not regenerated
d Two-sample t test
fer limitations associated with fluidized and packed col- additional immunoglobulin (impurity) in the hybridoma
culture or simply an inherent inability of immobilizedumns when they are used for direct hemoperfusion [29].
The high affinity of the antibodies could potentially re- BBM.1 to retain its binding activity. Even though our
initial b2m concentrations were relatively low, the ad-duce patient b2m concentrations below those obtainable
with a low-affinity, hydrophobic adsorbent. The larger sorption kinetics of our system should not be negatively
affected by higher initial b2m concentrations. Providedb2m concentration difference between the plasma and
the adsorptive surface should result in an apparent in- that a high-capacity immunoadsorbent medium is used,
b2m concentrations that are characteristic of ESRDcreased rate of adsorption. The high specificity of the
antibodies should avoid the indiscriminate loss of desir- should be cleared. Vallar et al have reported high immo-
bilization efficiencies (67%, ds 5 0.9 mg b2m/mL settledable molecules. In addition, immunoadsorption could
potentially be used in clinical trials as a diagnostic tool to gel) of other Sepharose CL-4B-immobilized anti-human
b2m monoclonal antibodies [14]. A VFPR containing anhelp determine whether b2m clearance is the underlying
mechanism responsible for the therapeutic response of immunoadsorbent medium of 0.9 mg b2m/mL settled
gel should remove clinically relevant quantities of b2mnonspecific treatments. Some investigators have shown
that a hydrophobic adsorbent, thought to be selective for within the allotted treatment time. A VFPR containing
300 mL of gel is potentially capable of removing 270 mgb2m, removed various cytokines [30]. Therefore, defined
immunoadsorbents could be targeted toward these mole- of b2m. Depending on the initial plasma b2m levels, ses-
sion duration, and the type of dialysis membrane used,cules to help understand their role in the pathogenesis
of DRA or other morbidities associated with ESRD. up to 250 mg b2m per session can be removed via filtra-
tion and nonspecific adsorption (about 100 mg per 4-hourIt is very difficult, and at times not practical, to repro-
duce in vitro all of the parameters that are characteristic session on average) [31]. However, the key difference is
the high affinity and specificity of immunoadsorption.of an in vivo or ex vivo situation. Pathologic b2m levels
and larger b2m distribution volumes were not tested be- High affinity is important because it helps maintain a
high apparent adsorption rate within the VFPR. We arecause of the limited available quantities of the BBM.1
monoclonal antibody. However, the kinetics of b2m re- currently developing a mathematical model that should
describe our data and predict b2m removal from a 70 kgmoval from blood with the VFPR using the immobilized
BBM.1 antibody as a model system could be evaluated. patient using the VFPR.
To date, the emphasis of attention to remove b2mThe lower than expected immobilization yield of BBM.1
using the CNBr activated agarose beads was also ob- from blood under clinically relevant conditions have
been filtration and hydrophobic interactions between theserved with agarose immobilized protein A, which spe-
cifically binds the Fc region of an IgG antibody. This b2m and the adsorptive media [1, 7, 10, 32]. However,
the specificity and affinity of these approaches continuephenomenon could be attributed to the expression of an
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noaffinity chromatography. J Chromatogr B Biomed Sci Appl 496:to be a concern. We overcame these obstacles by using
194–200, 1989monoclonal antibody technology. The BBM.1 antibody, 13. Nakano H, Gomi H, Shibasaki T, et al: An experimental study on
produced by mammalian cell culture, had the required selective elimination of b2-microglobulin using immunoadsorption
method in patients with chronic renal failure. Biomater Artif Cellsaffinity to lower b2m concentrations below the detectable
Immobilization Biotechnol 19:61–69, 1991limit of the RIA. We anticipate that this kind of affinity
14. Vallar L, Costa PMP, Teixeira A, et al: Immunoadsorption pro-
and specificity can be obtained using scFv at a much cedure as a potential method for the specific b2-microglobulin
removal from plasma of patients with chronic renal failure. J Chro-lower cost [33]. The cost reductions associated with bac-
matogr B Biomed Sci Appl 664:97–106, 1995terial or yeast fermentations versus mammalian cell cul-
15. Suggs SV, Wallace BW, Hirose T, et al: Use of synthetic oligonu-
tures should make the use of immunoaffinity-based tech- cleotides as hybridization probes: Isolation of cloned cDNA se-
nologies more attractive. Future studies will focus on quences for human b2-microglobulin. Proc Natl Acad Sci USA 78:
6613–6617, 1981using a library of recombinant antibody fragments and
16. Pace CN, Vajdos F, Fee L, et al: How to measure and predict thevarious immobilization chemistries to achieve a higher molar adsorption coefficient of a protein. Protein Sci 4:2411–2423,
b2m binding site density. Furthermore, the efficacy of 1995
17. Brodsky FM, Bodmer WF, Parham P: Characterization of a mono-the VFPR suggests that this technology could be tailored
clonal anti-b2-microglobulin antibody and its use in the geneticfor the treatment of a range of pathologies characterized
and biochemical analysis of major histocompatibility antigens. Eur
by elevated circulating concentrations of unwanted com- J Immunol 9:536–545, 1979
18. Parham P, Androlewicz MJ, Holmes NJ, Rothenberg BE: Argi-pounds, such as genetic disorders, liver failure, autoim-
nine 45 is a major part of the antigenic determinant of human b2-mune disease, sepsis, or drug overdoses.
microglobulin recognized by mouse monoclonal antibody BBM.1.
J Biol Chem 10:6179–6185, 1983
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